Literature DB >> 17058221

The half-life of hepatitis B virions.

John M Murray1, Robert H Purcell, Stefan F Wieland.   

Abstract

The virion half-life of hepatitis B virus (HBV) is currently estimated at approximately 1 day. This estimate has been obtained from drug perturbation experiments with reverse transcriptase inhibitors. However, the analyses of those experiments have not considered the export of virions produced from preformed mature DNA-containing HBV capsids in infected cells. Data from 3 acutely infected chimpanzees indicates that there is approximately 10-fold more total intracellular HBV DNA than HBV DNA in blood, and therefore the half-life of virions for chimpanzees during acute infection is 10-fold shorter at 3.8 hours than the half-life associated with export of total intracellular HBV DNA. Mathematical model simulations duplicating the viral dynamics observed in drug perturbation experiments suggest a half-life of at most 4.4 hours for HBV virions in chronically infected humans, significantly shorter than current estimates, but consistent with the half-lives of virions for hepatitis C virus and HIV. This faster turnover of HBV in blood indicates a correspondingly higher replication rate and risk of mutation against hepatitis B antiviral therapy. In conclusion, we find the half-life of HBV virions is approximately 4 hours, significantly shorter than current estimates of 1 day. This new value is consistent with virion half-life estimates for HIV and hepatitis C virus.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17058221     DOI: 10.1002/hep.21364

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

1.  Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.

Authors:  Ruy M Ribeiro; Georgios Germanidis; Kimberly A Powers; Bertrand Pellegrin; Paul Nikolaidis; Alan S Perelson; Jean-Michel Pawlotsky
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

2.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 3.  Experimental models and therapeutic approaches for HBV.

Authors:  Maura Dandri; Marc Lütgehetmann; Jörg Petersen
Journal:  Semin Immunopathol       Date:  2012-08-17       Impact factor: 9.623

Review 4.  Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues.

Authors:  Zhuo-Lun Song; Yu-Jun Cui; Wei-Ping Zheng; Da-Hong Teng; Hong Zheng
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

Review 5.  Clinical impact of hepatitis B and C virus envelope glycoproteins.

Authors:  Hélène Jeulin; Aurélie Velay; John Murray; Evelyne Schvoerer
Journal:  World J Gastroenterol       Date:  2013-02-07       Impact factor: 5.742

Review 6.  Application of nucleoside analogues to liver transplant recipients with hepatitis B.

Authors:  Zhuo-Lun Song; Yu-Jun Cui; Wei-Ping Zheng; Da-Hong Teng; Hong Zheng
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

7.  Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection.

Authors:  Dieter Glebe; Heike Lorenz; Wolfram H Gerlich; Scott D Butler; Ilia A Tochkov; Bud C Tennant; Paul Cote; Stephan Menne
Journal:  J Virol       Date:  2008-12-03       Impact factor: 5.103

8.  Antiviral resistance and hepatitis B therapy.

Authors:  Marc G Ghany; Edward C Doo
Journal:  Hepatology       Date:  2009-05       Impact factor: 17.425

Review 9.  Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

Authors:  Vincent Soriano; Alan S Perelson; Fabien Zoulim
Journal:  J Antimicrob Chemother       Date:  2008-04-25       Impact factor: 5.790

10.  Intrahepatic expression of genes affiliated with innate and adaptive immune responses immediately after invasion and during acute infection with woodchuck hepadnavirus.

Authors:  Clifford S Guy; Patricia M Mulrooney-Cousins; Norma D Churchill; Tomasz I Michalak
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.